Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New Molecule Could Lead to HIV Vaccine

By Kenny Walter | October 27, 2017

Researchers believe a new molecule discovered could someday lead to a successful HIV vaccine.

A team from the University of Maryland (UMD) and Duke University has created a protein-sugar vaccine candidate in an animal model that has shown the ability to stimulate an immune response against the sugars that form a protective shield around HIV.

The researchers designed a vaccine candidate using an HIV protein fragment linked to a sugar group that,  when injected into rabbits, stimulated the antibody responses against the sugar shield in four different HIV strains.

The protein fragment comes from gp120—a protein that covers HIV like a protective envelop, which is covered by a sugar shield that bolsters HIV’s defenses.

“An obstacle to creating an effective HIV vaccine is the difficulty of getting the immune system to generate antibodies against the sugar shield of multiple HIV strains,” Lai-Xi Wang, a professor of chemistry and biochemistry at UMD, said in a statement. “Our method addresses this problem by designing a vaccine component that mimics a protein-sugar part of this shield.”

Researchers have previously targeted gp120, but the sugar shield on HIV resembles sugars found in the human body and does not stimulate a strong immune response.

Also there are more than 60 strains of HIV that exist, with the virus being able to mutate frequently.

These researchers focused on a small fragment of the protein that is common among different HIV strains. They used a synthetic chemistry method to combine the gp120 fragment with a sugar molecule that is also shared among HIV strains.

They then injected the protein-sugar vaccine candidate into rabbits and found that the rabbits’ immune system produced antibodies that physically bound to gp120 that was present in four dominant strains of HIV.

When they injected rabbits with a vaccine candidate that contained the protein fragment without the sugar group, they found that the antibodies bound to gp120 were from only one HIV strain.

“This result was significant because producing antibodies that directly target the defensive sugar shield is an important step in developing immunity against the target and therefore the first step in developing a truly effective vaccine,” Wang said.

While the rabbits’ antibodies bound to gp120, they did not prevent live HIV from injecting cells.

“We have not hit a home run yet,” Wang said. “But the ability of the vaccine candidate to raise substantial antibodies against the sugar shield in only two months is encouraging; other studies took up to four years to achieve similar results.

“This means that our molecule is a relatively strong inducer of the immune response,” he added.

The researchers will now conduct longer-term studies in combination with other vaccine candidates to hone in on the specific areas of gp120 the antibodies are binding to and determine how they can increase the antibodies’ effectiveness at neutralizing HIV.

The study was published in Cell Chemical Biology.         

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE